SLC2A1 and Parkinson disease: Furthermore, GLUT changes seen in these non-transgenic models are quite resembling to those found in AD/PD patients, e.g. decreased levels of GLUT3 were found in the brain of AD patients post mortem (An et al. 2018; Liu et al. 2009) accompanied by an increase in GLUT2 expression which most likely occurs in astrocytes (Liu et al. 2008).